Dr. Yaron is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
210 East Grand Ave
South San Francisco, CA 94080Phone+1 650-837-7000
Education & Training
David Geffen School of Medicine at UCLAClass of 2011
University of RochesterResidency, Internal Medicine, 2001 - 2004
Certifications & Licensure
CA State Medical License 2004 - 2016
Publications & Presentations
PubMed
- 29 citationsA phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.Heather A. Wakelee, Scott N. Gettinger, Jeffrey A. Engelman, Pasi A. Jänne, Howard Jack West
Cancer Chemotherapy and Pharmacology. 2017-03-28 - 27 citationsPhase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.Hiroshi Nokihara, Makoto Nishio, Noboru Yamamoto, Yutaka Fujiwara, Hidehito Horinouchi
Clinical Lung Cancer. 2019-05-01 - 9 citationsAssessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induce...Dale Miles, Steven Lacy, David R. Wada, Steve Milwee, Yifah Yaron
Cancer Chemotherapy and Pharmacology. 2017-06-20
Press Mentions
Harpoon Therapeutics Announces Leadership ChangeApril 7th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
